A team of researchers at the Harvard T. H. Chan School of Public Health has illuminated a critical player in cholesterol metabolism that acts as a molecular guardian in cells to help maintain cholesterol levels within a safe, ...
Nov 16, 2017
0
228
In the first year of availability of the cholesterol lowering medications PCSK9 inhibitors, fewer than 1 in 3 adults initially prescribed one of these inhibitors actually received it, owing to a combination of out-of-pocket ...
Sep 27, 2017
0
0
(HealthDay)—In patients with type 2 diabetes being treated with a dipeptidyl peptidase-4 inhibitor (DPP4-I), use of anagliptin (ANA) may improve low-density lipoprotein cholesterol (LDL-C) levels, with the effect mediated, ...
Sep 19, 2017
0
1
(HealthDay)—Clinical benefit of reduced low-density lipoprotein cholesterol (LDL-C) levels may depend on the corresponding reduction in apolipoprotein B (apoB)-containing lipoprotein particles, according to a study published ...
Aug 29, 2017
0
0
Scientists from UCLA and the Howard Hughes Medical Institute successfully used a gene that suppresses cholesterol levels as part of a treatment to reduce plaque in mice with a disorder called familial hypercholesterolemia. ...
Aug 28, 2017
0
47
(HealthDay)—At its current price, the addition of evolocumab to standard therapy in patients with atherosclerotic cardiovascular disease generally exceeds accepted cost-effectiveness thresholds, according to a study published ...
Aug 25, 2017
0
0
An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater ...
Aug 22, 2017
0
0
(HealthDay)—There is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy, according to a study published in the Aug. 17 issue of the New England Journal ...
Aug 17, 2017
0
1
(HealthDay)—A biomarker-based model provides a new tool for the prediction of cardiovascular (CV) death in patients with stable coronary heart disease (CHD), according to a study published in the Aug. 15 issue of the Journal ...
Aug 9, 2017
0
4
(HealthDay)—The glucagon receptor blocker REGN1193, a fully human monoclonal antibody, seems safe and tolerable enough for further development, according to a study published online July 28 in Diabetes, Obesity and Metabolism.
Aug 4, 2017
0
0
